These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35820743)

  • 1. Efficacy and safety of guanabenz acetate treatment for non-alcoholic fatty liver disease: a study protocol for a randomised investigator-initiated phase IIa study.
    Iwaki M; Kessoku T; Tanaka K; Ozaki A; Kasai Y; Yamamoto A; Takahashi K; Kobayashi T; Nogami A; Honda Y; Ogawa Y; Imajo K; Yoneda M; Kobayashi N; Saito S; Nakajima A
    BMJ Open; 2022 Jul; 12(7):e060335. PubMed ID: 35820743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease.
    Kessoku T; Kobayashi T; Ozaki A; Iwaki M; Honda Y; Ogawa Y; Imajo K; Saigusa Y; Yamamoto K; Yamanaka T; Usuda H; Wada K; Yoneda M; Saito S; Nakajima A
    BMJ Open; 2020 Sep; 10(9):e037961. PubMed ID: 32907904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
    Loomba R; Morgan E; Watts L; Xia S; Hannan LA; Geary RS; Baker BF; Bhanot S
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):829-838. PubMed ID: 32553151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Administration of small-molecule guanabenz acetate attenuates fatty liver and hyperglycemia associated with obesity.
    Yoshino S; Iwasaki Y; Matsumoto S; Satoh T; Ozawa A; Yamada E; Kakizaki S; Trejo JAO; Uchiyama Y; Yamada M; Mori M
    Sci Rep; 2020 Aug; 10(1):13671. PubMed ID: 32792584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study).
    Ozaki A; Yoneda M; Kessoku T; Iwaki M; Kobayashi T; Honda Y; Ogawa Y; Imajo K; Sakai E; Taguri M; Yamanaka T; Iwasaki T; Kurihashi T; Saito S; Nakajima A
    Contemp Clin Trials Commun; 2020 Mar; 17():100516. PubMed ID: 31956725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study.
    Cusi K; Alkhouri N; Harrison SA; Fouqueray P; Moller DE; Hallakou-Bozec S; Bolze S; Grouin JM; Jeannin Megnien S; Dubourg J; Ratziu V
    Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):889-902. PubMed ID: 34560015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of an isoenergetic low Glycaemic Index (GI) diet on liver fat accumulation and gut microbiota composition in patients with non-alcoholic fatty liver disease (NAFLD): a study protocol of an efficacy mechanism evaluation.
    Al-Awadi A; Grove J; Taylor M; Valdes A; Vijay A; Bawden S; Gowland P; Aithal G
    BMJ Open; 2021 Oct; 11(10):e045802. PubMed ID: 34620653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study.
    Amin NB; Darekar A; Anstee QM; Wong VW; Tacke F; Vourvahis M; Lee DS; Charlton M; Alkhouri N; Nakajima A; Yunis C
    BMJ Open; 2022 Mar; 12(3):e056159. PubMed ID: 35354614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety analysis of Danggui Shaoyao Powder for the treatment of non-alcoholic fatty liver disease: study protocol for a randomized, double-blind, placebo-controlled clinical trial.
    Huang Q; An Z; Xin X; Sun Q; Gao S; Lv S; Xu X; Yang S; Lu F; Yuan J; Zhao Y; Hu Y; Liu P; Feng Q
    BMC Complement Med Ther; 2023 Apr; 23(1):126. PubMed ID: 37076843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study design.
    Kessoku T; Imajo K; Kobayashi T; Honda Y; Kato T; Ogawa Y; Tomeno W; Kato S; Higurashi T; Yoneda M; Kirikoshi H; Kubota K; Taguri M; Yamanaka T; Usuda H; Wada K; Saito S; Nakajima A
    Contemp Clin Trials; 2018 Jun; 69():40-47. PubMed ID: 29627620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of Jian-Pi Huo-Xue granule for non-alcoholic fatty liver disease: study protocol for a randomized, double-blind, placebo-controlled trial.
    Sun Y; Chen G; Chen S; Wang Y; Hu Y; Zhao Y
    Trials; 2022 Jun; 23(1):455. PubMed ID: 35655225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial).
    Kuchay MS; Krishan S; Mishra SK; Choudhary NS; Singh MK; Wasir JS; Kaur P; Gill HK; Bano T; Farooqui KJ; Mithal A
    Diabetologia; 2020 Nov; 63(11):2434-2445. PubMed ID: 32865597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
    McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
    JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of polyphenol supplementation on hepatic steatosis, intima-media thickness and non-invasive vascular elastography in obese adolescents: a pilot study protocol.
    Moretti JB; Drouin A; Truong C; Youn E; Cloutier A; Alvarez F; Paganelli M; Grzywacz K; Jantchou P; Dubois J; Levy E; El Jalbout R
    BMJ Open; 2024 Jan; 14(1):e074882. PubMed ID: 38296273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non-alcoholic fatty liver disease: Results from two early-phase randomized trials.
    Beysen C; Schroeder P; Wu E; Brevard J; Ribadeneira M; Lu W; Dole K; O'Reilly T; Morrow L; Hompesch M; Hellerstein MK; Li K; Johansson L; Kelly PF
    Diabetes Obes Metab; 2021 Mar; 23(3):700-710. PubMed ID: 33289350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Harrison SA; Bashir MR; Guy CD; Zhou R; Moylan CA; Frias JP; Alkhouri N; Bansal MB; Baum S; Neuschwander-Tetri BA; Taub R; Moussa SE
    Lancet; 2019 Nov; 394(10213):2012-2024. PubMed ID: 31727409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials.
    Mantovani A; Byrne CD; Scorletti E; Mantzoros CS; Targher G
    Diabetes Metab; 2020 Nov; 46(6):427-441. PubMed ID: 31923578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial.
    Naeini F; Namkhah Z; Tutunchi H; Rezayat SM; Mansouri S; Jazayeri-Tehrani SA; Yaseri M; Hosseinzadeh-Attar MJ
    Trials; 2021 Nov; 22(1):801. PubMed ID: 34774104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.